Fulranumab
Term · Oncology and biomedicine · MLC-T-ONC-013783
A monoclonal antibody directed against nerve growth factor (NGF) with potential analgesic activity. Upon administration, fulranumab binds to NGF, preventing its binding to and activation of the NGF receptors TrkA and p75NTR. Inhibition of the NGF pathway may prevent the perception of pain and may induce analgesia. NGF, a neurotrophic factor that plays a key role in neuropathic and inflammatory-induced pain, promotes hyperalgesia and allodynia.
| Identifier | MLC-T-ONC-013783 |
|---|---|
| Field | Oncology and biomedicine |
| Synonyms | Anti-NGF monoclonal antibody JNJ-42160443; anti-nerve growth factor monoclonal antibody JNJ-42160443 |
| References | National Cancer Institute Thesaurus (CC BY 4.0) |
Record as JSON
{
"id": "MLC-T-ONC-013783",
"term": "Fulranumab",
"field": "Oncology and biomedicine",
"definition": "A monoclonal antibody directed against nerve growth factor (NGF) with potential analgesic activity. Upon administration, fulranumab binds to NGF, preventing its binding to and activation of the NGF receptors TrkA and p75NTR. Inhibition of the NGF pathway may prevent the perception of pain and may induce analgesia. NGF, a neurotrophic factor that plays a key role in neuropathic and inflammatory-induced pain, promotes hyperalgesia and allodynia.",
"synonyms": [
"Anti-NGF monoclonal antibody JNJ-42160443",
"anti-nerve growth factor monoclonal antibody JNJ-42160443"
],
"references": [
"National Cancer Institute Thesaurus"
],
"url": "https://mlchart.com/terminology/oncology/fulranumab/"
}
Record 7,630 of 17,717 in Oncology and biomedicine terminology (MLC-0111). Request the full dataset.